LAKEFRONT BIOTHERAPEUTICS
LIVE

Serial Number

99620958

Owner

Galapagos NV

Attorney

Alexandra MacKay

Filing Date

Jan 28, 2026

Add to watchlist:

No watchlists yet
View on USPTO

LAKEFRONT BIOTHERAPEUTICS Trademark

Serial Number: 99620958

LAKEFRONT BIOTHERAPEUTICS is a trademark filed by Galapagos NV on January 28, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Galapagos NV (19 trademarks)

Mechelen B-2800 , BE

Entity Type: 03

LAKEFRONT BIOTHERAPEUTICS NV

SCHALIËNHOEVEDREEF 20 BOX T
MECHELEN 2800 , BE

Entity Type: 03

Trademark Details

Filing Date

January 28, 2026

Registration Date

Not Registered

Goods & Services

Medical and scientific research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services, namely, configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; pharmaceutical drug development services

medical and clinical pharmaceutical advisory and consultancy services

Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, cancer, hematological cancer, solid tumors, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, dermatomyositis, urticaria, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, cancer, hematological cancer, solid tumors, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, dermatomyositis, urticaria, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 28, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 28, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 28, 2026 TROA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 26, 2026 ASGN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 28, 2026 GNRN
NON-FINAL ACTION E-MAILED
May 28, 2026 GNRT
NON-FINAL ACTION WRITTEN
May 28, 2026 CNRT
ASSIGNED TO EXAMINER
May 27, 2026 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
May 26, 2026 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 26, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Jan 28, 2026 MAFR
NEW APPLICATION ENTERED
Jan 28, 2026 NWAP